The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat

  title={The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat},
  author={John F. Cryan and Anna M Redmond and John P Kelly and Brian E. Leonard},
  journal={European Neuropsychopharmacology},

Chronic Administration of 5-HT1A Receptor Agonist Relieves Depression and Depression-Induced Hypoalgesia

It is demonstrated that chronic administration of 8-OH-DPAT reversed the depression-induced decrease in pain sensitivity in rats, suggesting that 5-HT1A receptor may play a role in the Depression-associated hypoalgesia.

The role of serotonin receptor subtypes in treating depression: a review of animal studies

The involvement of 5- HT receptors in the antidepressant-like effects of SSRIs is complex and involves the orchestration of stimulation and blockade at different 5-HT receptor subtypes.

Association of 5-HT1A Receptors with Affective Disorders

The purpose of this chapter is to analyze and discuss the current information about 5-HT 1A -R-mediated signaling cascades, the intracellular signaling of 5- HT 1A-R, in addition to their expression and pharmacology that are important to treat- ment of affective disorders symptoms.

5‐HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response

It is concluded that selective targeting of 5‐HT receptors may lead to a faster acting and more efficient antidepressant response.



Anticonflict effects of the 5-HT1A compound flesinoxan

It would appear that flesinoxan should be a useful compound in the clinical management of anxiety after being examined under a procedure that has proved to be a reliable and sensitive method for detecting novel anxiolytic drugs believed to produce their effects at the 5-HT 1A receptor subtype.

Some behavioural and neurochemical effects of ipsapirone in two rodent models of depression

It can be concluded that ipsapirone shows antidepressant-like activity in the forced swim test and the OB rat model of depression, and did not attenuate the reductions in noradrenaline and serotonin in the frontal cortex of OB animals.

Pilot study of flesinoxan, a 5‐HT1A agonist, in major depression: Effects on sleep REM latency and body temperature

Flesinoxan is a highly potent and selective 5‐HT1A full agonist, active in several models of depression. In this pilot open study, flesinoxan (4 mg/d) was administered orally for 4 weeks in 16 major

An open study of oral flesinoxan, a 5‐HT1A receptor agonist, in treatment‐resistant depression

The observations suggested that flesinoxan is an antidepressant agent and that it may be of particular value in some difficult, treatment-resistant depressions.

Further Characterization of the Discriminative Stimulus Induced by Flesinoxan

The present results are in favour of a 5-HT1A mechanism for the discriminative stimulus of flesinoxan and consistent with the results of previous drug discrimination studies with fles inoxan.